Coronavirus

Pulse Oximetry Market size is set to grow by USD 1.18 billion from 2024-2028, Increasing prevalence of chronic respiratory diseases to boost the market growth, Technavio

NEW YORK, July 19, 2024 /PRNewswire/ -- The global pulse oximetry market  size is estimated to grow by USD 1.18 billion from 2024-2028,…

4 months ago

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable…

4 months ago

A Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricides

SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

4 months ago

Services PMI® at 48.8%; June 2024 Services ISM® Report On Business®

Business Activity Index at 49.6%; New Orders Index at 47.3%; Employment Index at 46.1%; Supplier Deliveries Index at 52.2% TEMPE,…

5 months ago

Sapiens Accelerates Growth for Medical Professional Liability Insurers

Sapiens' expanded offering maximizes business value for MPL insurers, supporting growth and retention   ROCHELLE PARK, N.J., July 2, 2024…

5 months ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

5 months ago

Rapid Dose Therapeutics Vaccine Delivery Study Receives Mitacs Accelerate Grant

Burlington, Ontario--(Newsfile Corp. - June 25, 2024) - Rapid Dose Therapeutics Corp. ("RDT" or the "Company") trading on the Canadian…

5 months ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader…

5 months ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and…

5 months ago

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in…

5 months ago